# OnCo record naxitamab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/naxitamab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "naxitamab" ;
  schema:name "Naxitamab"@en ;
  schema:description "Naxitamab is a humanised anti-GD2 antibody from Memorial Sloan Kettering, given as an outpatient with GM-CSF for relapsed neuroblastoma in bone or marrow."@en ;
  schema:url <https://onco.cc/drugs/naxitamab/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Naxitamab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q103085694> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Naxitamab> ;
  onco:status "approved" ;
  onco:modality "Monoclonal antibody (anti-GD2, humanised)" ;
  schema:alternateName "Danyelza" ;
  onco:approval "US 2020: Relapsed/refractory high-risk neuroblastoma in bone or bone marrow with partial response, minor response or stable disease, with GM-CSF (accelerated)" ;
  onco:acceleratedApproval "US 2020-11-25: In combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy." ;
  onco:cancers <https://onco.cc/cancers/neuroblastoma/>, <https://onco.cc/cancers/neuroblastoma-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/gd2/> ;
  onco:companies <https://onco.cc/companies/y-mabs/> ;
  onco:trials <https://onco.cc/trials/naxitamab-201/> .